UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 296

Sortiert nach

The Next Decade of Immune Checkpoint Therapy

Cancer discovery, 2021-04, Vol.11 (4), p.838-857

2021

Link zum Volltext

Verfügbarkeit prüfen

B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes

Science translational medicine, 2014-08, Vol.6 (248), p.248ra107

2014

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors

Journal of cancer research and clinical oncology, 2023-07, Vol.149 (8), p.5429-5436

2023

Link zum Volltext

Verfügbarkeit prüfen

Cell shape change and invagination of the cephalic furrow involves reorganization of F-actin

Developmental biology, 2015-06, Vol.402 (2), p.192-207

2015

Link zum Volltext

Verfügbarkeit prüfen

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e002919

2021

Link zum Volltext

Verfügbarkeit prüfen

Schistosomiasis vaccines

Human vaccines, 2011-11, Vol.7 (11), p.1192-1197

2011

Link zum Volltext

Verfügbarkeit prüfen

Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor

Cancers, 2020-12, Vol.12 (12), p.3755

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint therapy—current perspectives and future directions

Cell, 2023-04, Vol.186 (8), p.1652-1669

2023

Link zum Volltext

Verfügbarkeit prüfen

EXPAREL® (Long-Acting Liposomal Bupivacaine) Use for Popliteal Nerve Block in Postoperative Pain Control after Ankle Fracture Fixation

Pain research & management, 2020, Vol.2020, p.1-5

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e006262

2023

Link zum Volltext

Verfügbarkeit prüfen

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Journal for immunotherapy of cancer, 2021-07, Vol.9 (7), p.e002850

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy

European journal of heart failure, 2021-10, Vol.23 (10), p.1725-1735

2021

Link zum Volltext

Verfügbarkeit prüfen

A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events

Cancer cell, 2022-03, Vol.40 (3), p.249-251

2022

Link zum Volltext

Verfügbarkeit prüfen

Cancer Cell–Extrinsic Roles for the Androgen Receptor in Prostate Cancer

Endocrinology (Philadelphia), 2023-04, Vol.164 (6)

2023

Link zum Volltext

Verfügbarkeit prüfen

S185 Characteristics and Outcomes of Cancer Patients With Pre-existing Microscopic Colitis After Exposure to Immune Checkpoint Inhibitors

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e135-e135

2022

Link zum Volltext

Verfügbarkeit prüfen

Distributed Nonlinear MPC of Multi-Agent Systems With Data Compression and Random Delays

IEEE transactions on automatic control, 2016-03, Vol.61 (3), p.817-822

2016

Link zum Volltext
IEEE_Xplore

Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients

Journal of neuro-oncology, 2021-07, Vol.153 (3), p.441-446

2021

Link zum Volltext

Verfügbarkeit prüfen

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

Cell reports. Medicine, 2022-04, Vol.3 (4), p.100613-100613, Article 100613

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Current treatment options in oncology, 2024-05, Vol.25 (5), p.617-618

2024

Link zum Volltext

Verfügbarkeit prüfen

Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Current treatment options in oncology, 2024, Vol.25 (1), p.66-83

2024

Link zum Volltext

Verfügbarkeit prüfen

Headache and focal neurologic signs following exposure to spicy aroma as an initial presentation of moyamoya disease

Interdisciplinary neurosurgery : Advanced techniques and case management, 2014-12, Vol.1 (4), p.81-83

2014

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment

Translational andrology and urology, 2020-01, Vol.9 (Suppl 1), p.S56-S65

2020

Link zum Volltext

Verfügbarkeit prüfen

Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer

Endocrinology (Philadelphia), 2023-06, Vol.164 (6), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.135-135

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 296

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(260)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The Next Decade of Immune Checkpoint Therapy

B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes

Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors

Cell shape change and invagination of the cephalic furrow involves reorganization of F-actin

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Schistosomiasis vaccines

Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor

Immune checkpoint therapy—current perspectives and future directions

EXPAREL® (Long-Acting Liposomal Bupivacaine) Use for Popliteal Nerve Block in Postoperative Pain Control after Ankle Fracture Fixation

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy

A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events

Cancer Cell–Extrinsic Roles for the Androgen Receptor in Prostate Cancer

S185 Characteristics and Outcomes of Cancer Patients With Pre-existing Microscopic Colitis After Exposure to Immune Checkpoint Inhibitors

Distributed Nonlinear MPC of Multi-Agent Systems With Data Compression and Random Delays

Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Headache and focal neurologic signs following exposure to spicy aroma as an initial presentation of moyamoya disease

Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment

Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors

Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer

Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC)

Suchergebnisse filtern